Zynteglo Market Report 2026

Zynteglo Market Overview

• The Zynteglo market growth in the historic period has been driven by increasing prevalence of transfusion-dependent beta-thalassemia, limitations of lifelong blood transfusion therapies • Market expansion is supported by increasing commercialization of gene editing therapies, rising investments in rare disease gene treatments • Growth Driver: Rising Thalassemia Incidence Fuels Growth Of The Market • Market Trend: Expansion of Gene Therapy Access as Commercial Adoption Accelerates • North America was the largest region in 2025.

What Is Covered Under Zynteglo Market?

Zynteglo is a gene therapy for treating beta-thalassemia, a genetic blood disorder. It involves modifying a patient's stem cells to produce functional hemoglobin, addressing the root cause of the disease. The treatment aims to reduce or eliminate the need for blood transfusions in patients with transfusion-dependent beta-thalassemia. The main types of indications for zynteglo are beta-thalassemia and sickle cell disease. Beta-thalassemia is a genetic blood disorder where the body produces insufficient beta-globin, leading to anemia and requiring medical intervention such as blood transfusions in severe cases. It is distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies, catering to various end users such as adults, pediatrics, and geriatrics.

What Is The Zynteglo Market Growth Forecast?

The growth in the forecast period can be attributed to increasing commercialization of gene editing therapies, rising investments in rare disease gene treatments, expansion of personalized medicine infrastructure, growing focus on curative hematology solutions, increasing healthcare funding for genetic disorders. Major trends in the forecast period include increasing adoption of gene therapy for blood disorders, rising use of one-time curative treatments, growing focus on stem cell-based therapies, expansion of personalized genetic medicine, enhanced emphasis on long-term disease correction.

Global Zynteglo Market Segmentation

1) By Indication: Beta -Thalassemia, Sickle Cell Disease 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By End User: Adult, Pediatric, Geriatric

What Are The Drivers Of The Zynteglo Market?

The rising incidence of thalassemia is expected to propel the growth of the zynteglo market going forward. Thalassemia refers to a group of inherited blood disorders characterized by the body producing inadequate hemoglobin, leading to anemia. The rising incidence of thalassemia can be attributed to factors such as high carrier rates in specific populations, genetic inheritance through consanguineous marriages, increased migration, lack of awareness and screening, and improved diagnosis and survival rates. Zynteglo helps reduce the incidence of thalassemia by providing a one-time gene therapy that enables patients to produce healthy hemoglobin, potentially eliminating the need for regular blood transfusions. For instance, in November 2024, according to the American Society of Hematology, a US-based professional organization, in 2023, the prevalence of beta-thalassemia was approximately 3,665 cases, corresponding to a rate of 1.07 per 100,000 individuals. Therefore, the rising incidence of thalassemia drives the growth of the zynteglo industry. The rise in healthcare infrastructure is expected to propel the growth of the zynteglo market going forward. Healthcare infrastructure refers to the comprehensive framework of physical facilities, organizational structures, equipment, personnel, and systems necessary for delivering effective and efficient healthcare services to the population. The rise in healthcare infrastructure can be attributed to population growth, medical technology advancements, government investments, the increasing burden of chronic diseases, urbanization, medical tourism, private sector participation, and an aging population. The rise in healthcare infrastructure creates an ecosystem that supports advanced treatments such as zynteglo, from diagnosis and logistics to patient care. For instance, in January 2025, according to Sports Medical, a United Kingdom-based healthcare industry publication, health work starting on site in the UK totalled £4.8 billion in 2024, representing an 18% increase year-on-year from 2023. Therefore, the rise in healthcare infrastructure drives the growth of the zynteglo industry.

Key Players In The Global Zynteglo Market

Major companies operating in the zynteglo market are Bluebird bio Inc

Global Zynteglo Market Trends and Insights

Major companies operating in the Zynteglo market are concentrating on technological advancement in the form of commercialisation scale-up and real-world implementation of gene therapies, such as improvements in patient-start processes, supply-chain readiness, and centre-of-excellence networks that enable safe, timely delivery of autologous cell and gene treatments. Commercialisation scale-up and real-world implementation refers to the set of systems, processes and enabling technologies (manufacturing scale, logistics for cryopreserved/autologous products, centre accreditation, and payer/health-system pathways) that turn a regulatory approval into routine patient access at scale. For instance, in January 2024, bluebird bio, Inc., a US-based biotechnology company focused on severe genetic diseases, announced that 26 patient starts were completed in 2023 across its commercial portfolio including 20 for ZYNTEGLO and 6 for SKYSONA marking a pivotal moment in transitioning the therapy from approval to meaningful real-world use. This milestone demonstrates that the treatment moved beyond isolated approvals into clinical practice, providing treated patients with access to a potentially curative option. It also validates the company’s commercial and operational model (patient identification, centre coordination and supply logistics) and supplies early real-world evidence that can support payer discussions and wider adoption.

Regional Insights

North America was the largest region in the zynteglo market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Zynteglo Market?

The zynteglo market consists of sales of autologous gene therapy, one-time curative therapy and cell therapy products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Zynteglo Market Report 2026?

The zynteglo market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the zynteglo industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.